Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Relutrigine · PRAX-562, PRX-0001511

Small molecule · developed by Praxis Precision Medicines

Phase 3 Most advanced trial
PRAX Developer
1 Registered trials

What is Relutrigine?

Relutrigine (PRAX-562) is an oral drug studied in developmental and epileptic encephalopathy 1.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PRAX-562, PRX-0001511
Drug type
Small molecule
Therapy area
Neurology
Developer
Praxis Precision Medicines (PRAX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
AW5C5XHM4W

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07010471 Phase 3 Developmental and Epileptic Encephalopathy 1 Active not recruiting PRAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Developmental and Epileptic Encephalopathy 1

More from Praxis Precision Medicines

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PRAX page.

Follow PRAX, the company behind Relutrigine

See PRAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRAX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.